These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8719233)

  • 1. Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy.
    Yamada Y; Shibuya F; Hamada J; Sawada Y; Iga T
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):131-45. PubMed ID: 8719233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.
    Koella WP
    Eur J Clin Pharmacol; 1985; 28 Suppl():55-63. PubMed ID: 2865151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.
    Yamada Y; Matsuyama K; Ito K; Sawada Y; Iga T
    J Pharmacokinet Biopharm; 1995 Oct; 23(5):463-78. PubMed ID: 8656342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship.
    Yamada Y; Ito K; Nakamura K; Sawada Y; Iga T
    Biol Pharm Bull; 1993 Dec; 16(12):1251-9. PubMed ID: 7907513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetic analysis of therapeutic doses of beta-blockers for angina pectoris based on receptor occupancy theory--relationship between beta 1-receptor occupancy or vasodilative action and dose].
    Yamada Y; Matsuyama K; Takayanagi R; Kotaki H; Sawada Y; Iga T
    Yakugaku Zasshi; 1999 Jul; 119(7):495-501. PubMed ID: 10434801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.
    Kaila T; Iisalo E; Lehtonen A; Saarimaa H
    Cardiovasc Drugs Ther; 1993 Dec; 7(6):839-49. PubMed ID: 7912102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbances of sleep and wakefulness associated with the use of antihypertensive agents.
    Monti JM
    Life Sci; 1987 Oct; 41(17):1979-88. PubMed ID: 2890073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blockers and central nervous system side effects.
    McAinsh J; Cruickshank JM
    Pharmacol Ther; 1990; 46(2):163-97. PubMed ID: 1969642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
    Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
    Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersomnolence with beta-adrenergic blockers.
    Thachil J; Zeller JR; Kochar MS
    Chest; 1987 Nov; 92(5):943-4. PubMed ID: 3665616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs.
    Brismar K; Mogensen L; Wetterberg L
    Acta Med Scand; 1987; 221(2):155-8. PubMed ID: 2884812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced nightmares.
    Thompson DF; Pierce DR
    Ann Pharmacother; 1999 Jan; 33(1):93-8. PubMed ID: 9972389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
    Lemmer B; Winkler H; Ohm T; Fink M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):42-9. PubMed ID: 2864639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nightmares and panic disorder associated with carvedilol overdose.
    Maebara C; Ohtani H; Sugahara H; Mine K; Kubo C; Sawada Y
    Ann Pharmacother; 2002 Nov; 36(11):1736-40. PubMed ID: 12398570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties.
    Kostis JB; Rosen RC
    Circulation; 1987 Jan; 75(1):204-12. PubMed ID: 2878741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of lipid solubility and receptor selectivity of beta-adrenoceptor blocking drugs for the occurrence of symptoms and side-effects in out-patients.
    Theodoresen L; Brørs O
    J Intern Med; 1989 Jul; 226(1):17-23. PubMed ID: 2569025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs.
    McDevitt DG
    Eur Heart J; 1987 Dec; 8 Suppl M():9-14. PubMed ID: 2897304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers.
    Drayer DE
    Pharmacotherapy; 1987; 7(4):87-91. PubMed ID: 2891122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists.
    Yamada Y; Takayanagi R; Tsuchiya K; Ito K; Ohtani H; Sawada Y; Iga T
    J Ocul Pharmacol Ther; 2001 Jun; 17(3):235-48. PubMed ID: 11436944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS-related side-effects with metoprolol and atenolol.
    Cove-Smith JR; Kirk CA
    Eur J Clin Pharmacol; 1985; 28 Suppl():69-72. PubMed ID: 4054193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.